

Darell D Bigner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/262193/publications.pdf>

Version: 2024-02-01

145
papers

6,345
citations

81900

39
h-index

74163

75
g-index

150
all docs

150
docs citations

150
times ranked

7002
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).. Journal of Clinical Oncology, 2022, 40, e14015-e14015.	1.6	5
2	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nature Communications, 2021, 12, 352.	12.8	77
3	Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. Nature Communications, 2021, 12, 1858.	12.8	47
4	Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. , 2021, 9, e002203.		44
5	EXTH-59. GENERATION OF A THIRD GENERATION CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi176-vi176.	1.2	0
6	IMMU-26. SAFETY AND EFFICACY OF PVSRIPO IN RECURRENT GLIOBLASTOMA: LONG-TERM FOLLOW-UP AND INITIAL MULTICENTER RESULTS. Neuro-Oncology, 2021, 23, vi97-vi97.	1.2	4
7	CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi51-vi51.	1.2	2
8	BIOM-20. TUMOR-INTRINSIC AND PERIPHERAL FEATURES ASSOCIATE WITH SURVIVAL AFTER POLIO VIROTHERAPY IN RECURRENT GBM. Neuro-Oncology, 2021, 23, vi14-vi15.	1.2	0
9	Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nature Communications, 2020, 11, 524.	12.8	29
10	Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).. Journal of Clinical Oncology, 2020, 38, 2566-2566.	1.6	4
11	TMOD-17. ONCOLYTIC POLIOVIRUS AS A PROBE FOR MECHANISMS OF IMMUNE RESISTANCE IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii231-ii231.	1.2	0
12	CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG). Neuro-Oncology, 2020, 22, ii38-ii38.	1.2	3
13	Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. , 2019, 7, 142.		31
14	MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation. Cancer Research, 2019, 79, 3383-3394.	0.9	30
15	ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). Neuro-Oncology, 2019, 21, vi6-vi6.	1.2	1
16	ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES. Neuro-Oncology, 2019, 21, vi7-vi7.	1.2	5
17	EXTH-51. GENETICALLY STABLE POLIOVIRUS VECTOR PLATFORM FOR DIPG IMMUNOTHERAPY. Neuro-Oncology, 2019, 21, vi93-vi93.	1.2	0
18	Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. PLoS ONE, 2019, 14, e0210608.	2.5	14

#	ARTICLE	IF	CITATIONS
19	Sensitive and rapid detection of <i>TERT</i> promoter and <i>IDH</i> mutations in diffuse gliomas. <i>Neuro-Oncology</i> , 2019, 21, 440-450.	1.2	27
20	MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 57-64.	1.7	8
21	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2060-2060.	1.6	2
22	AJAP1 expression modulates glioma cell motility and correlates with tumor growth and survival. <i>International Journal of Oncology</i> , 2018, 52, 47-54.	3.3	8
23	Application of mutagen sensitivity assay in a glioma case-control study. <i>Toxicology Reports</i> , 2018, 5, 183-188.	3.3	4
24	T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 4175-4186.	7.0	402
25	A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 3611-3631.	7.0	39
26	Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. <i>Journal of Neuro-Oncology</i> , 2018, 138, 489-498.	2.9	5
27	Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. <i>Cancer Research</i> , 2018, 78, 256-264.	0.9	82
28	Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities. <i>Cancer Research</i> , 2018, 78, 36-50.	0.9	35
29	IMMU-31. DYSFUNCTIONAL STING PATHWAY SIGNALING COMPROMISES INNATE IMMUNITY IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi127-vi128.	1.2	1
30	GENE-42. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi112-vi112.	1.2	0
31	EXTH-79. BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS. <i>Neuro-Oncology</i> , 2018, 20, vi102-vi102.	1.2	0
32	PDTM-46. POLIOVIRUS RECEPTOR (CD155) EXPRESSION IN PEDIATRIC BRAIN TUMORS MEDIATES ONCOLYSIS OF MEDULLOBLASTOMA AND PLEOMORPHIC XANTHOASTROCYTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi213-vi213.	1.2	0
33	ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2018, 20, vi9-vi9.	1.2	2
34	TMOD-33. ESTABLISHMENT AND PRELIMINARY EVALUATION OF BEVACIZUMAB-RESISTANT GLIOMA XENOGRAFT MODELS. <i>Neuro-Oncology</i> , 2018, 20, vi275-vi275.	1.2	0
35	ATIM-27. INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES. <i>Neuro-Oncology</i> , 2018, 20, vi7-vi7.	1.2	0
36	GENE-01. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi102-vi103.	1.2	0

#	ARTICLE	IF	CITATIONS
37	HGG-22. PHASE 1b STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN. <i>Neuro-Oncology</i> , 2018, 20, i93-i93.	1.2	2
38	Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 1329-1340.	1.9	7
39	The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. <i>Nature Communications</i> , 2018, 9, 2087.	12.8	124
40	Recurrent Glioblastoma Treated with Recombinant Poliovirus. <i>New England Journal of Medicine</i> , 2018, 379, 150-161.	27.0	570
41	Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells. <i>Scientific Reports</i> , 2018, 8, 12507.	3.3	5
42	Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 696-702.	1.7	38
43	Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12641-e12641.	1.6	5
44	Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. <i>Molecular Cancer Research</i> , 2017, 15, 507-520.	3.4	41
45	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. <i>Clinical Cancer Research</i> , 2017, 23, 1898-1909.	7.0	215
46	Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial. <i>Applied Microbiology and Biotechnology</i> , 2017, 101, 2747-2766.	3.6	27
47	Development and validation of a cell-based fluorescent method for measuring antibody affinity. <i>Journal of Immunological Methods</i> , 2017, 442, 49-53.	1.4	3
48	Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1697-1704.	2.5	44
49	Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	180
50	<i>Cic</i> Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation. <i>Cancer Research</i> , 2017, 77, 6097-6108.	0.9	46
51	Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display. <i>Protein Engineering, Design and Selection</i> , 2017, 30, 639-647.	2.1	5
52	Immunotoxin Therapy for Lung Cancer. <i>Chinese Medical Journal</i> , 2017, 130, 607-612.	2.3	1
53	Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13532-e13532.	1.6	2
54	A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 102-102.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors. <i>Oncotarget</i> , 2017, 8, 76644-76655.	1.8	27
56	Immunotoxin and bcl-2 inhibitor combination therapy targeting chondroitin sulfate proteoglycan 4.. <i>Journal of Clinical Oncology</i> , 2017, 35, 74-74.	1.6	0
57	Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2017, 35, e13533-e13533.	1.6	0
58	Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors. <i>Cancer Research</i> , 2016, 76, 5143-5150.	0.9	28
59	IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma. <i>Scientific Reports</i> , 2016, 6, 27012.	3.3	21
60	Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats. <i>Investigational New Drugs</i> , 2016, 34, 149-158.	2.6	10
61	CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains. <i>Cancer Immunology Research</i> , 2016, 4, 259-268.	3.4	90
62	MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. <i>Cancer Cell</i> , 2016, 29, 49-60.	16.8	95
63	Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2061-2061.	1.6	17
64	Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).. <i>Journal of Clinical Oncology</i> , 2016, 34, e13518-e13518.	1.6	6
65	EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery. <i>Receptors & Clinical Investigation</i> , 2016, 3, .	0.9	11
66	Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. <i>Oncotarget</i> , 2016, 7, 79828-79841.	1.8	53
67	IMCT-19COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM). <i>Neuro-Oncology</i> , 2015, 17, v111.4-v112.	1.2	0
68	Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. <i>Oncolimmunology</i> , 2015, 4, e994374.	4.6	41
69	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. <i>Neuro-Oncology</i> , 2015, 17, 854-861.	1.2	335
70	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. <i>Nature</i> , 2015, 519, 366-369.	27.8	429
71	Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 65-74.	2.9	22
72	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2068-2068.	1.6	9

#	ARTICLE	IF	CITATIONS
73	Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).. Journal of Clinical Oncology, 2015, 33, e13030-e13030.	1.6	0
74	EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma. PLoS ONE, 2014, 9, e94281.	2.5	99
75	AT-21 * FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology, 2014, 16, v13-v13.	1.2	4
76	Induction of Viral, 7-Methyl-Guanosine Cap-Independent Translation and Oncolysis by Mitogen-Activated Protein Kinase-Interacting Kinase-Mediated Effects on the Serine/Arginine-Rich Protein Kinase. Journal of Virology, 2014, 88, 13135-13148.	3.4	45
77	Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nature Genetics, 2014, 46, 726-730.	21.4	148
78	Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. Journal of Clinical Neuroscience, 2014, 21, 189-190.	1.5	94
79	Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM).. Journal of Clinical Oncology, 2014, 32, TPS2106-TPS2106.	1.6	1
80	Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).. Journal of Clinical Oncology, 2014, 32, 3069-3069.	1.6	0
81	Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody. Cancer Immunology Research, 2013, 1, 163-167.	3.4	61
82	A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma. Oncoimmunology, 2013, 2, e26852.	4.6	11
83	Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. Oncoimmunology, 2013, 2, e26757.	4.6	30
84	Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.. Journal of Clinical Oncology, 2013, 31, e13015-e13015.	1.6	1
85	Rindopepimut. Drugs of the Future, 2013, 38, 147.	0.1	19
86	Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2094-2094.	1.6	4
87	Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2011, 29, e519-e520.	1.6	1
88	Reply to M.S. Lesniak. Journal of Clinical Oncology, 2011, 29, 3105-3106.	1.6	9
89	Allan J. Yates, MD, PhD, FRCP(C) (1943â€“2010). Journal of Neuropathology and Experimental Neurology, 2010, 69, 1272-1273.	1.7	0
90	Digital karyotyping: a powerful tool for cancer gene discovery. , 2006, , .		1

#	ARTICLE	IF	CITATIONS
91	Poliovirus receptor CD155-targeted oncolysis of glioma. <i>Neuro-Oncology</i> , 2004, 6, 208-217.	1.2	116
92	Title is missing!. <i>Journal of Neuro-Oncology</i> , 2003, 64, 161-176.	2.9	6
93	tumor-derived xenografts in athymic mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 83-87.	2.3	28
94	Therapeutic activity of the topoisomerase I inhibitor J-107088 [6- N -(1-hydroxymethyl-2-hydroxy) ethylamino-12,13-dihydro-13-(β-D -gluco pyranosyl)- 5H -indolo[2,3- a]-pyrrolo[3,4- c]-carbazole-5,7(6H) Tj ETQq0 0 0 rgBT /Overlock and <i>Pharmacology</i> , 2001, 48, 250-254.	2.3	32
95	Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 413-416.	2.3	14
96	Long term response in a patient with neoplastic meningitis secondary to melanoma treated with 131I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab?) ₂ . <i>Cancer</i> , 2001, 91, 1809-1813.	4.1	35
97	Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. <i>International Journal of Cancer</i> , 2000, 88, 962-969.	5.1	68
98	Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 345-349.	2.3	31
99	O ⁶ -Benzylguanine-mediated enhancement of nitrosourea activity in Merck central nervous system tumor xenografts - implications for clinical trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 437-440.	2.3	18
100	EGFRvIII as a promising target for antibody-based brain tumor therapy. <i>Brain Tumor Pathology</i> , 2000, 17, 71-78.	1.7	46
101	Glioma-associated Antigen Expression in Oligodendroglial Neoplasms: Tenascin and Epidermal Growth Factor Receptor. <i>Journal of Histochemistry and Cytochemistry</i> , 2000, 48, 1103-1110.	2.5	56
102	EGFRvIII: an oncogene deletion mutant cell surface receptor target expressed by multiple tumour types. <i>Expert Opinion on Therapeutic Targets</i> , 2000, 4, 497-514.	1.0	5
103	Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. <i>Journal of Neuro-Oncology</i> , 1999, 44, 233-241.	2.9	18
104	Monoclonal antibody therapy of human gliomas: current status and future approaches. <i>Cancer and Metastasis Reviews</i> , 1999, 18, 451-464.	5.9	51
105	Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR). <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 73-79.	2.3	17
106	Modulation of cyclophosphamide activity by O ⁶ -alkylguanine-DNA alkyltransferase. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 80-85.	2.3	47
107	Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 41, 485-490.	2.3	57
108	Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 479-482.	2.3	17

#	ARTICLE	IF	CITATIONS
109	Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). <i>Biochemical Journal</i> , 1997, 324, 855-861.	3.7	166
110	Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors. <i>Journal of Neuro-Oncology</i> , 1997, 35, 259-273.	2.9	7
111	Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 409-414.	2.3	6
112	Radioimmunotherapy with ^{125}I -Particle Emitting Radioimmunoconjugates. <i>Acta Oncologica</i> , 1996, 35, 373-379.	1.8	115
113	Enhancement of melphalan activity by inhibition of DNA polymerase- β and DNA polymerase- δ . <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 38, 349-354.	2.3	6
114	L-Amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 39, 179-186.	2.3	7
115	Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 39, 187-191.	2.3	91
116	Treatment of patients with pineoblastoma with high dose cyclophosphamide. , 1996, 26, 387-392.		23
117	In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line. <i>Glycoconjugate Journal</i> , 1996, 13, 391-399.	2.7	9
118	Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma. <i>Medical and Pediatric Oncology</i> , 1995, 25, 190-196.	1.0	29
119	Tumor antigens in astrocytic gliomas. <i>Glia</i> , 1995, 15, 244-256.	4.9	110
120	Prognostic implications of chromosome 17p deletions in human medulloblastomas. <i>Journal of Neuro-Oncology</i> , 1995, 24, 39-45.	2.9	123
121	Cyclophosphamide therapy of medulloblastoma: From the laboratory to the clinic and back again (and again and again). <i>Journal of Neuro-Oncology</i> , 1995, 24, 103-108.	2.9	12
122	Phase I studies of treatment of malignant gliomas and neoplastic meningitis with ^{131}I -radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab?) ₂ -a preliminary report. <i>Journal of Neuro-Oncology</i> , 1995, 24, 109-122.	2.9	125
123	The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 379-384.	2.3	3
124	Immunohistochemistry of the Glial Fibrillary Acidic Protein: Basic and Applied Considerations. <i>Brain Pathology</i> , 1994, 4, 221-228.	4.1	71
125	Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 171-174.	2.3	78
126	Monoclonal antibodies to malignant human gliomas. <i>Molecular and Chemical Neuropathology</i> , 1992, 17, 137-146.	1.0	13

#	ARTICLE	IF	CITATIONS
127	Loss of heterozygosity for 10q loci in human gliomas. <i>Genes Chromosomes and Cancer</i> , 1992, 5, 75-82.	2.8	108
128	Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 15-21.	2.3	11
129	Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 27, 278-284.	2.3	8
130	Medulloblastoma: tumor biological and clinical perspectives. <i>Journal of Neuro-Oncology</i> , 1991, 11, 1-15.	2.9	59
131	L-Buthionine-Sulfoximine-Mediated Radiosensitization in Experimental Interstitial Radiotherapy of Intracerebral D-54 MG Glioma Xenografts in Athymic Mice. <i>Neurosurgery</i> , 1990, 26, 255-260.	1.1	14
132	Determination of Gangliosides in Six Human Primary Medulloblastomas. <i>Journal of Neurochemistry</i> , 1990, 55, 1322-1326.	3.9	26
133	The Localisation of Radiolabeled Murine Monoclonal Antibody 81C6 and its Fab Fragment in Human Glioma Xenografts in Athymic Mice. <i>British Journal of Neurosurgery</i> , 1988, 2, 179-191.	0.8	19
134	Effect of Glutamate Analogues on Brain Tumor Cell Lines. <i>Journal of Neurochemistry</i> , 1985, 45, 1186-1192.	3.9	7
135	Immunolocalization of monoclonal antibody-defined extracellular matrix antigens in human brain tumors. <i>Journal of Neuro-Oncology</i> , 1985, 3, 181-186.	2.9	35
136	Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein. <i>Journal of Cellular Biochemistry</i> , 1985, 28, 183-195.	2.6	113
137	Vasoactive drugs produce selective changes in flow to experimental brain tumors. <i>Annals of Neurology</i> , 1985, 18, 712-715.	5.3	20
138	Patterns of the early, gross chromosomal changes in malignant human gliomas. <i>Hereditas</i> , 1984, 101, 103-113.	1.4	115
139	Study of Glial Fibrillary Acidic Protein in a Human Glioma Cell Line Grown in Culture and as a Solid Tumor. <i>Journal of Neurochemistry</i> , 1983, 40, 460-467.	3.9	55
140	The Morphologic Response of Cell Lines Derived from Human Gliomas to Dibutyl Adenosine 3'. <i>Journal of Neuropathology and Experimental Neurology</i> , 1981, 40, 230-246.	1.7	19
141	Relationship of in Vitro Morphologic and Growth Characteristics of Established Human Glioma-derived Cell Lines to Their Tumorigenicity in Athymic Nude Mice. <i>Journal of Neuropathology and Experimental Neurology</i> , 1981, 40, 390-409.	1.7	69
142	REDOX PROPERTIES OF CYTOCHROME OXIDASE AND VASCULAR REACTIVITY OF ASTROCYTOMAS AND NEUROBLASTOMAS IN VIVO. <i>Journal of Neurochemistry</i> , 1979, 32, 1371-1377.	3.9	4
143	Heterotransplantation of Human Craniopharyngiomas in Athymic "Nude" Mice. <i>Neurosurgery</i> , 1979, 4, 308-314.	1.1	27
144	The role of the subependymal plate in avian sarcoma virus brain tumor induction:. <i>Acta Neuropathologica</i> , 1977, 38, 1-6.	7.7	30

#	ARTICLE	IF	CITATIONS
145	Improved Techniques for Staining and Enumerating Focus Formation in Viral Infectivity Assays. Applied Microbiology, 1974, 28, 156-157.	0.6	0